Table 4.
Hazard ratios for kidney outcomes in association with randomization to enalapril for the Treatment Trial
| Enalapril | Placebo | Interaction with time p-value | Period of Follow-up | |||
|---|---|---|---|---|---|---|
| < 6 weeks | 6 weeks to 1 year | > 1 year | ||||
| Creatinine Increase By ≥0.3 mg/dl | ||||||
| Unadjusted HR (95% CI) | 1.37 (1.17, 1.61) | Ref | 0.013 | 1.49 (1.11, 2.00) | 1.51 (1.12, 2.04) | 1.21 (0.94, 1.56) |
| *Adjusted HR (95% CI) | 1.37 (1.17, 1.61) | Ref | 0.014 | 1.48 (1.10, 1.99) | 1.50 (1.11, 2.03) | 1.21 (0.95, 1.56) |
| Decline in eGFR By >30% | ||||||
| Unadjusted HR (95% CI) | 1.44 (1.21, 1.72) | Ref | 0.043 | 1.41 (1.01, 1.98) | 1.65 (1.16, 2.34) | 1.36 (1.05, 1.76) |
| *Adjusted HR (95% CI) | 1.43 (1.20, 1.70) | Ref | 0.056 | 1.38 (0.98, 1.94) | 1.62 (1.14, 2.29) | 1.36 (1.05, 1.76) |
| Decline in eGFR By >40% | ||||||
| Unadjusted HR (95% CI) | 1.34 (1.04, 1.75) | Ref | 0.005 | 2.64 (1.32, 5.29) | 1.21 (0.74, 1.99) | 1.16 (0.82, 1.65) |
| *Adjusted HR (95% CI) | 1.32 (1.02, 1.72) | Ref | 0.003 | 2.60 (1.30, 5.21) | 1.19 (0.73, 1.96) | 1.14 (0.80, 1.62) |
| Incident eGFR<30 ml/min/1.73 m2 | ||||||
| Unadjusted HR (95% CI) | 1.29 (0.88, 1.89) | Ref | 0.014 | 4.24 (1.60, 11.25) | 0.81 (0.41, 1.61) | 1.03 (0.59, 1.82) |
| *Adjusted HR (95% CI) | 1.48 (1.01, 2.17) | Ref | 0.012 | 4.71 (1.78, 12.50) | 0.92 (0.47, 1.84) | 1.21 (0.69, 2.14) |
Analyses performed using Cox proportional hazards ratios. Given significant interaction with time in the Treatment trial, follow-up period was divided into 3 separate intervals of <6-weeks, 6-weeks to 1 year, and >1 year.
*
Adjusted for age, sex, race, NYHA functional class, current smoking, ischemic etiology of left ventricular dysfunction, diuretic use and baseline eGFR.
eGFR = estimated glomerular filtration rate; HR = hazard ratio; CI = confidence interval; ref = reference